First approved for adults in 2022, the therapy is now cleared for children 12-18 with symptomatic obstructive hypertrophic cardiomyopathy.
News|Expert Interviews|September 8, 2020
REDUCE-IT Trial Data Updates: Key Takeaways
A discussion on recent data updates from the REDUCE-IT trial, and their practical implications for physicians managing cardiovascular risk.
Advertisement
A discussion on recent data updates from the REDUCE-IT trial, and their practical implications for physicians managing cardiovascular risk.
Advertisement
Related to this article
Researchers outline individual peripheral arterial disease burden as well as the most at-risk patient populations and treatment recommendations.
Study findings tie continuous glucose monitoring measures to elevated cardiovascular risk in adults without diabetes.
An American Heart Association scientific statement shows earlier risk factors and social barriers driving cardiovascular disparities in Hispanic adults.
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Advertisement
Advertisement
Trending on Drug Topics
1
What Is HIV PrEP and Who Needs It Most?
2
Normal vs. Concerning COVID-19 Vaccine Reactions: A Pharmacist's Guide
3
Validating Fear Before Facts: A Framework for COVID-19 Hesitancy
4
Why Rural Pharmacies Are Essential Infrastructure in US Health Care
5